On­coMed’s bad, no good, dis­as­trous month con­tin­ues as an­oth­er PhII flops, PhIb tri­al is shut­tered

A few days ago, shares of On­coMed $OMED were blitzed by the news that its top drug dem­cizum­ab had flopped in a Phase II study, fol­low­ing it up with the news that Bay­er by­passed a tie-up on two oth­er key pro­grams. This morn­ing the biotech added that its drug tarex­tum­ab plus chemo al­so failed a Phase II study. And in­ves­ti­ga­tors de­cid­ed to drop a Phase Ib tri­al of bron­tic­tuzum­ab af­ter they de­ter­mined that the drug reg­i­men was not tol­er­at­ed by pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA